Cetuximab (erbitux)
W Bou-Assaly, S Mukherji - American Journal of …, 2010 - Am Soc Neuroradiology
Cetuximab, a recombinant chimeric monoclonal antibody, has been successfully used in the
treatment of the head and neck and colorectal cancers. We present a review of its …
treatment of the head and neck and colorectal cancers. We present a review of its …
Cetuximab (Imclone/Merck/Bristol-Myers Squibb).
MS Kies, PM Harari - Current opinion in investigational drugs …, 2002 - europepmc.org
ImClone, in collaboration with licensees, Merck KGaA and Bristol-Myers Squibb (BMS), are
developing cetuximab, a chimeric monoclonal antibody that blocks the epidermal growth …
developing cetuximab, a chimeric monoclonal antibody that blocks the epidermal growth …
Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer
SKA Blick, LJ Scott - Drugs, 2007 - Springer
Cetuximab (Erbitux®) is a human-mouse chimeric monoclonal antibody, which competitively
binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR) …
binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR) …
The biological properties of cetuximab
Cetuximab is a recombinant chimeric human murine immunoglobulin G1 antibody that binds
to the extra-cellular domain of epidermal growth factor receptor with a higher affinity than …
to the extra-cellular domain of epidermal growth factor receptor with a higher affinity than …
Cetuximab: a review of its use in squamous cell carcinoma of the head and neck
JE Frampton - Drugs, 2010 - Springer
Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …
Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer
SF Wong - Clinical therapeutics, 2005 - Elsevier
BACKGROUND:: Cetuximab is a recombinant human/mouse chimeric epidermal growth
factor receptor (EGFR) monoclonal antibody. It was approved by the US Food and Drug …
factor receptor (EGFR) monoclonal antibody. It was approved by the US Food and Drug …
Cetuximab in the treatment of squamous cell carcinoma of the head and neck
P Specenier, JB Vermorken - Expert review of anticancer therapy, 2011 - Taylor & Francis
The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …
Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
M Merlano, M Occelli - Therapeutics and clinical risk management, 2007 - Taylor & Francis
Cetuximab is a monoclonal antibody able to inhibit and to degrade the transmembrane
receptor Her-1, also known as epidermal growth factor receptor (EGFR). The inhibition of …
receptor Her-1, also known as epidermal growth factor receptor (EGFR). The inhibition of …
Cetuximab in the treatment of head and neck cancer
J Bernier - Expert review of anticancer therapy, 2006 - Taylor & Francis
Approaches to the treatment of locally advanced and recurrent and/or metastatic squamous
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …
The role of cetuximab in the management of head and neck cancers
P Kabolizadeh, GJ Kubicek, DE Heron… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: The standard of care for patients with locally-advanced head and neck cancer
is chemoradiation or surgical resection followed by radiation treatment with or without …
is chemoradiation or surgical resection followed by radiation treatment with or without …
